Healthtech solutions company Brain+ A/S (Nasdaq First North:BRAINP) announced on Tuesday that Ayla – your CST Assistant has received registration with the UK Medicines and Healthcare products Regulatory Agency (MHRA).
This registration follows successful certification as a Class I Medical Device Software under UK Conformity Assessment (UKCA) regulations. With the UKCA marking secured, Ayla – your CST Assistant is poised for commercial launch as the only medical device software in the UK providing Cognitive Stimulation Therapy (CST) for dementia patients.
Ayla will become commercially available on various digital distribution platforms within the next few days, facilitating outreach to NHS sites and positioning Brain+ to sign initial sales contracts in Q4 2024. As a pioneering software solution, Ayla enhances the delivery of group-based CST, which is endorsed in NICE guidelines as the primary non-pharmacological treatment for dementia. It allows for tailored CST delivery and minimizes preparation time by providing curated content developed with leading experts.
Upcoming certifications will ensure compliance with NHS data privacy, cyber security and usability standards, including NHS DSPT and NHS DTAC requirements. A CREST-accredited penetration test will also be conducted, enabling Ayla – your CST Assistant to be included in the G-Cloud 14 procurement platform by the end of October, streamlining access for NHS trusts.
Median Technologies secures funding for eyonis Lung Cancer Screening software
MicroAire Surgical Instruments acquires NEOSYAD
UCB launches 320 mg/2 mL single-injection administration option for BIMZELX (bimekizumab-bkzx) in US
Concept Medical reports first patient enrolled in MagicTouch SCB trial in peripheral artery disease
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Revvity and Element Biosciences partner to enhance neonatal sequencing for IVD testing
Implantica publishes real-world data supporting RefluxStop efficacy
Abingdon Health subsidiary awarded GBP500,000 contract
NanoVibronix completes pilot phase of UroShield study at University of Michigan
Inogen secures FDA clearance for SIMEOX 200 Airway Clearance Device
Microtech commences human clinical trial of microsensor platform for heart failure
Humacyte Global receives approval from FDA for Symvess
Defense Diagnostics launches DEFENT ONE All-In-One Fentanyl Detection Device in US
HeartBeam secures FDA clearance for innovative at-home heart monitoring device